In 2019, U.S. Senator Marco Rubio (R-FL) released Made in China 2025 and the Future of American Industry , where he detailed critical vulnerabilities in America’s medical supply chain. The 2019 report warned of America’s overreliance on China for pharmaceutical production. This was proven during the COVID-19 pandemic when the United States experienced generic drug shortages and the further erosion of domestic pharmaceutical manufacturing jobs.

Rubio and colleagues introduced a new version of the Further Strengthening America’s Supply Chains and National Security Act to combat America’s dependence on China for pharmaceuticals and to address associated supply chain risks that lead […]

See also  DIRECTOR, HUMANITARIAN AND GLOBAL HEALTH POLICY

By Donato